Literature DB >> 32544096

Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda.

Jessica L Prodger1,2,3, Adam A Capoferri3, Katherine Yu2, Jun Lai3, Steven J Reynolds3,4,5, Jingo Kasule5, Taddeo Kityamuweesi5, Paul Buule5, David Serwadda5,6, Kyungyoon J Kwon3, Katherine Schlusser3, Craig Martens7, Eileen Scully3, Yun-Hee Choi2, Andrew D Redd3,4, Thomas C Quinn3,4.   

Abstract

HIV-1 infection remains incurable owing to the persistence of a viral reservoir that harbors integrated provirus within host cellular DNA. Increasing evidence links sex-based differences in HIV-1 immune responses and pathogenesis; however, little is known about differences in HIV-1 infection persistence. Here, we quantified persistent HIV-1 infection in 90 adults on suppressive antiretroviral therapy in Rakai, Uganda (57 female patients). Total HIV-1 DNA was quantified by PCR, and replication-competent provirus by quantitative viral outgrowth assay (QVOA). Immune phenotyping of T cell subsets and plasma biomarkers was also performed. We found that whereas both sexes had similar total HIV DNA levels, female patients had significantly fewer resting CD4+ T cells harboring replication-competent virus, as measured by viral outgrowth in the QVOA. Factors associated with viral outgrowth differed by sex; notably, frequency of programmed cell death 1 (PD1+) CD4+ T cells correlated with reservoir size in male but not female patients. The sex-based differences in HIV-1 persistence observed in this cohort warrant additional research, especially given the widespread use of the QVOA to assess reservoir size and current explorations of PD1 agonists in cure protocols. Efforts should be made to power future cure studies to assess outcomes in both male and female patients.

Entities:  

Keywords:  AIDS/HIV; Chemokines; Sex hormones; T cells

Mesh:

Substances:

Year:  2020        PMID: 32544096      PMCID: PMC7453892          DOI: 10.1172/jci.insight.139287

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  33 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

Authors:  Paul U Cameron; Suha Saleh; Georgina Sallmann; Ajantha Solomon; Fiona Wightman; Vanessa A Evans; Genevieve Boucher; Elias K Haddad; Rafick-Pierre Sekaly; Andrew N Harman; Jenny L Anderson; Kate L Jones; Johnson Mak; Anthony L Cunningham; Anthony Jaworowski; Sharon R Lewin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

3.  17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription.

Authors:  Erika L Szotek; Srinivas D Narasipura; Lena Al-Harthi
Journal:  Virology       Date:  2013-06-12       Impact factor: 3.616

Review 4.  Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

Authors:  Rowena E Johnston; Mary M Heitzeg
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

5.  Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.

Authors:  Gregory M Laird; Daniel I S Rosenbloom; Jun Lai; Robert F Siliciano; Janet D Siliciano
Journal:  Methods Mol Biol       Date:  2016

6.  Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

Authors:  Slim Fourati; Philippe Flandre; Ruxandra Calin; Guislaine Carcelain; Cathia Soulie; Sidonie Lambert-Niclot; Almoustapha Maiga; Zaina Ait-Arkoub; Roland Tubiana; Marc-Antoine Valantin; Brigitte Autran; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2013-11-01       Impact factor: 5.790

7.  Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.

Authors:  Biswajit Das; Curtis Dobrowolski; Benjamin Luttge; Saba Valadkhan; Nicolas Chomont; Rowena Johnston; Peter Bacchetti; Rebecca Hoh; Monica Gandhi; Steven G Deeks; Eileen Scully; Jonathan Karn
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

8.  HIV Prevention Efforts and Incidence of HIV in Uganda.

Authors:  M Kate Grabowski; David M Serwadda; Ronald H Gray; Gertrude Nakigozi; Godfrey Kigozi; Joseph Kagaayi; Robert Ssekubugu; Fred Nalugoda; Justin Lessler; Thomas Lutalo; Ronald M Galiwango; Fred Makumbi; Xiangrong Kong; Donna Kabatesi; Stella T Alamo; Steven Wiersma; Nelson K Sewankambo; Aaron A R Tobian; Oliver Laeyendecker; Thomas C Quinn; Steven J Reynolds; Maria J Wawer; Larry W Chang
Journal:  N Engl J Med       Date:  2017-11-30       Impact factor: 91.245

9.  A quantitative approach for measuring the reservoir of latent HIV-1 proviruses.

Authors:  Katherine M Bruner; Zheng Wang; Francesco R Simonetti; Alexandra M Bender; Kyungyoon J Kwon; Srona Sengupta; Emily J Fray; Subul A Beg; Annukka A R Antar; Katharine M Jenike; Lynn N Bertagnolli; Adam A Capoferri; Joshua T Kufera; Andrew Timmons; Christopher Nobles; John Gregg; Nikolas Wada; Ya-Chi Ho; Hao Zhang; Joseph B Margolick; Joel N Blankson; Steven G Deeks; Frederic D Bushman; Janet D Siliciano; Gregory M Laird; Robert F Siliciano
Journal:  Nature       Date:  2019-01-30       Impact factor: 49.962

10.  Defective proviruses rapidly accumulate during acute HIV-1 infection.

Authors:  Katherine M Bruner; Alexandra J Murray; Ross A Pollack; Mary G Soliman; Sarah B Laskey; Adam A Capoferri; Jun Lai; Matthew C Strain; Steven M Lada; Rebecca Hoh; Ya-Chi Ho; Douglas D Richman; Steven G Deeks; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2016-08-08       Impact factor: 53.440

View more
  10 in total

1.  Sex differences in cytokine profiles during suppressive antiretroviral therapy.

Authors:  Christophe Vanpouille; Alan Wells; Timothy Wilkin; Jyoti S Mathad; Sheldon Morris; Leonid Margolis; Sara Gianella
Journal:  AIDS       Date:  2022-05-25       Impact factor: 4.632

2.  CCL5-Secreting Virtual Memory CD8+ T Cells Inversely Associate With Viral Reservoir Size in HIV-1-Infected Individuals on Antiretroviral Therapy.

Authors:  Wei Hu; Yan-Jun Li; Cheng Zhen; You-Yuan Wang; Hui-Huang Huang; Jun Zou; Yan-Qing Zheng; Gui-Chan Huang; Si-Run Meng; Jie-Hua Jin; Jing Li; Ming-Ju Zhou; Yu-Long Fu; Peng Zhang; Xiao-Yu Li; Tao Yang; Xiu-Wen Wang; Xiu-Han Yang; Jin-Wen Song; Xing Fan; Yan-Mei Jiao; Ruo-Nan Xu; Ji-Yuan Zhang; Chun-Bao Zhou; Jin-Hong Yuan; Lei Huang; Ya-Qin Qin; Feng-Yao Wu; Ming Shi; Fu-Sheng Wang; Chao Zhang
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

3.  Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.

Authors:  Eileen P Scully; Evgenia Aga; Athe Tsibris; Nancie Archin; Kate Starr; Qing Ma; Gene D Morse; Kathleen E Squires; Bonnie J Howell; Guoxin Wu; Lara Hosey; Scott F Sieg; Lynsay Ehui; Francoise Giguel; Kendyll Coxen; Curtis Dobrowolski; Monica Gandhi; Steve Deeks; Nicolas Chomont; Elizabeth Connick; Catherine Godfrey; Jonathan Karn; Daniel R Kuritzkes; Ronald J Bosch; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

4.  Sex Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging.

Authors:  Sara Gianella; Stephen A Rawlings; Curtis Dobrowolski; Masato Nakazawa; Antoine Chaillon; Matthew Strain; Laura Layman; Gemma Caballero; Eileen Scully; Brianna Scott; Caitleen Pacis; Kathleen M Weber; Alan Landay; Christy Anderson; Jonathan Karn
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

5.  Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs.

Authors:  Gregory D Kirk; Jacqueline Astemborski; Shruti H Mehta; Kristen D Ritter; Gregory M Laird; Rebeka Bordi; Rafick Sekaly; Janet D Siliciano; Robert F Siliciano
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

6.  Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size.

Authors:  Sherazaan D Ismail; Catherine Riou; Sarah B Joseph; Nancie M Archin; David M Margolis; Alan S Perelson; Tyler Cassidy; Melissa-Rose Abrahams; Matthew Moeser; Olivia D Council; Lyle R McKinnon; Farzana Osman; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald Swanstrom; Carolyn Williamson; Nigel J Garrett; Wendy A Burgers
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999

Review 7.  HIV Pathogenesis in the Human Female Reproductive Tract.

Authors:  Marta Rodriguez-Garcia; Kaleigh Connors; Mimi Ghosh
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-15       Impact factor: 5.495

8.  HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.

Authors:  F Harrison Omondi; Hanwei Sudderuddin; Aniqa Shahid; Natalie N Kinloch; Bradley R Jones; Rachel L Miller; Olivia Tsai; Daniel MacMillan; Alicja Trocha; Mark A Brockman; Chanson J Brumme; Jeffrey B Joy; Richard Liang; Bruce D Walker; Zabrina L Brumme
Journal:  mBio       Date:  2021-11-16       Impact factor: 7.867

Review 9.  Sex differences in HIV-1 persistence and the implications for a cure.

Authors:  Shringar Rao
Journal:  Front Glob Womens Health       Date:  2022-09-23

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.